Phase IIa Safety and Immunogenicity of a Therapeutic Vaccine, TA‐GW, in Persons with Genital Warts

Open Access
Publisher Website
Google Scholar
Abstract
A fusion protein vaccine consisting of human papillomavirus 6 L2E7 with Alhydrogel was developed for the treatment of genital warts. Twenty-seven sub